Relationship between prostate specific antigen new parameters and Gleason score and clinical stage
-
摘要: 目的:探讨前列腺癌患者PSAM (PSA mass) 和PSAMR (PSA mass ratio) 与Gleason评分、临床分期及预后的相关性。方法:2013年2月2015年12月期间我院经穿刺病理确诊为前列腺癌患者120例。采用Spearman等级相关回顾性分析PSAM和PSAMR与患者Gleason评分、临床分期及预后的相关关系。评价PSAM和PSAMR在前列腺癌诊疗及预后中的价值。结果:在全部患者中, Spearman等级相关分析显示PSAM和PSAMR与Gleason评分、临床分期及预后呈正相关 (P<0.01) 。结论:前列腺特异性抗原新参数PSAM和PSAMR对前列腺癌进展的评估及预测有重要意义。Abstract: Objective:To investigate the relationship between prostate specific antigen new parameters PSAM and PSAMR and Gleason score, clinical stage and prognosis.Method:We reviewed the clinical data of 120 patients with prostate cancer from Feb. 2013 to Dec. 2015.The spearman's correlation analysis was performed to determine the relationship between prostate specific antigen new parameters PSAM and PSAMR and Gleason score, clinical stage and prognosis.Result:The spearman's correlation analysis showed that PSAM and PSAMR in prostate cancer patients positively correlated with Gleason score, clinical stage and prognosis (P<0.01).Conclusion:PSA mass and PSA mass ratio appear to be keys to predicting the development and prognosis of prostate cancer.
-
Key words:
- PSA mass /
- PSA mass ratio /
- prostate cancer /
- clinical stage /
- Gleason score
-
-
[1] Rocco B, Grasso A, Sosnowski R, et al.PSA mass screening:is there enough evidence[J].Cent European J Urol, 2012, 65 (1):4-6.
[2] Wallner L P, Morgenstern H, McGree M E, et al.The effects of body mass index on changes in prostate-specific antigen levels and prostate volume over 15years of follow-up:implications for prostate cancer detection[J].Cancer Epidemiol Biomarkers Prev, 2011, 20 (3):501-508.
[3] Kubota Y, Seike K, Maeda S, et al.Relationship between prostate-specific antigen and obesity in prostate cancer screening:analysis of a large cohort in Japan[J].Int J Urol, 2011, 18 (1):72-75.
[4] Choi H C, Park J H, Cho B L, et al.The illusion of prostate-specific antigen decline in patients with metabolic syndrome and insulin resistance[J].BJU Int, 2011, 108 (11):1756-1761.
[5] Kryvenko O N, Diaz M, Matoso A, et al.Prostate-specific Antigen Mass Density--A Measure Predicting Prostate Cancer Volume and Accounting for Overweight and Obesity-related Prostate-specific Antigen Hemodilution[J].Urology, 2016, 90:141-147.
[6] 牛越, 徐勇, 张志宏, 等.FPSA/TPSA与PSAD在PSA灰区患者中前列腺癌诊断价值的比较[J].实用医学杂志, 2011, 27 (23):4303-4305.
[7] Noguchi S, Satomi Y, Sakai N, et al.Five-year results of prostate specific antigen (PSA) screening in Yokosuka City--comparative study between PSA-screened group and non-screened group[J].Hinyokika Kiyo, 2008, 54 (3):197-201.
[8] 吴杰, 赵睿哲, 黄源, 等.PSA“灰区”前列腺癌预测模型及随访系统的建立[J].中华泌尿外科杂志, 2016, 37 (4):280-283.
[9] Sivanandam A, Siva S, Bhandari M, et al.Variance inflation in sequential calculations of body surface area, plasma volume, and prostate-specific antigen mass[J].BJU Int, 2008, 102 (11):1573-1580.
[10] Bryniarski P, Paradysz A, Fryczkowski M.PSA mass as a marker of prostate cancer progression after radical prostatectomy[J].Med Sci Monit, 2011, 17 (2):CR104-109.
[11] Hong S K, Oh J J, Byun S S, et al.Value of prostatespecific antigen (PSA) mass ratio in the detection of prostate cancer in men with PSA levels of≤10ng/mL[J].BJU Int, 2012, 110 (2Pt 2):E81-85.
[12] 李方龙, 李德维, 殷小涛.前列腺特异性抗原新参数在前列腺癌诊断中的应用[J].现代泌尿外科杂志, 2015, 20 (12):871-874.
[13] Lee W K, Lee S, Hong S K, et al.Clinical utility of prostate-specific antigen mass ratio for prediction of prostate cancer detection on a repeated prostate biopsy[J].Int Braz J Urol, 2014, 40 (4):484-492.
[14] Nanri M, Nanri K, Fujiyama C, et al.Prostate-specific antigen assay using whole blood samples spotted on filter paper and its application to mass screening for prostate cancer[J].Int J Urol, 2007, 14 (6):505-509.
[15] 张华, 钟白云, 王新华, 等.血清t-PSA及f-PSA/t-PSA联合诊断前列腺癌的价值评价[J].中国现代医学杂志, 2014, 24 (7):24-27.
-
计量
- 文章访问数: 191
- PDF下载数: 257
- 施引文献: 0
下载: